Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...

PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that adult patients ...

PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial to ...

Cancer’s cruelest trick is its ability to disappear, only to reappear years later in a new organ or a familiar scar. The fear ...

After all those holiday indulgences, many people feel the need to hit the “reset” button with a detox or cleanse for a ...

Investing.com -- CG Oncology Inc (NASDAQ:CGON) stock surged 18.1% on Friday after the company announced it expects to deliver topline data from its Phase 3 PIVOT-006 clinical trial nearly a year ahead ...

Intuitive Surgical, Inc. stock: da Vinci robotics leader with 80% share, recurring revenue, fast procedure growth and solid ...

Global drugmakers face a battle in 2026 to secure higher prices for their prescription medicines in Europe after agreeing to ...

A new database targeting chronic urinary tract infections (UTIs)—a long-overlooked condition that may begin in childhood—is ...

A new database targeting chronic urinary tract infections (UTIs) – a long-overlooked condition that may begin in childhood – ...

Market OverviewThe global ostomy devices market is projected to grow at a healthy rate of 4–5% and is expected to reach approximately USD 3.2 billion by 2026. This steady expansion is driven by rising ...